TABLE A4.
EORTC QLQ-C30 Score Changes Compared With the Baseline
| Category | Visit | Total (N = 60) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No. | Mean | SD | Q1 | Median | Q3 | Minimum | Maximum | ||
| Total score | Cycle 3 – cycle 1 | 53 | –8.58 | 16.27 | –22.00 | –2.00 | 2.00 | –45.00 | 23.00 |
| Cycle 5 – cycle 1 | 47 | –10.04 | 18.13 | –21.00 | –4.00 | 3.00 | –54.00 | 23.00 | |
| Cycle 7 – cycle 1 | 42 | –9.02 | 18.08 | –21.00 | –2.00 | 3.00 | –48.00 | 17.00 | |
| Cycle 9 – cycle 1 | 14 | –18.64 | 17.93 | –32.00 | –18.50 | –1.00 | –46.00 | 4.00 | |
| Cycle 11 – cycle 1 | 9 | –14.56 | 15.13 | –26.00 | –14.00 | 1.00 | –34.00 | 5.00 | |
| Cycle 13 – cycle 1 | 5 | –6.20 | 13.81 | –13.00 | –11.00 | 6.00 | –23.00 | 10.00 | |
| Cycle 15 – cycle 1 | 2 | –3.50 | 13.44 | –13.00 | –3.50 | 6.00 | –13.00 | 6.00 | |
| EOT – cycle 1 | 15 | 7.33 | 23.00 | –6.00 | 8.00 | 23.00 | –32.00 | 55.00 | |
| Physical functioning | Cycle 3 – cycle 1 | 53 | 11.47 | 20.47 | –2.22 | 4.44 | 24.44 | –26.67 | 62.22 |
| Cycle 5 – cycle 1 | 47 | 14.94 | 24.43 | –2.22 | 8.89 | 28.89 | –28.89 | 73.33 | |
| Cycle 7 – cycle 1 | 42 | 11.69 | 25.17 | –6.67 | 3.33 | 24.44 | –20.00 | 68.89 | |
| Cycle 9 – cycle 1 | 14 | 22.22 | 25.83 | 0.00 | 13.33 | 51.11 | –17.78 | 62.22 | |
| Cycle 11 – cycle 1 | 9 | 17.04 | 20.25 | 6.67 | 13.33 | 31.11 | –11.11 | 46.67 | |
| Cycle 13 – cycle 1 | 5 | 2.22 | 16.56 | –8.89 | 2.22 | 11.11 | –17.78 | 24.44 | |
| Cycle 15 – cycle 1 | 2 | –3.33 | 17.28 | –15.56 | –3.33 | 8.89 | –15.56 | 8.89 | |
| EOT – cycle 1 | 15 | –11.56 | 29.07 | –33.33 | –13.33 | 4.44 | –75.56 | 37.78 | |
| Global health status | Cycle 3 – cycle 1 | 53 | 17.45 | 29.16 | 0.00 | 16.67 | 41.67 | –33.33 | 75.00 |
| Cycle 5 – cycle 1 | 47 | 19.68 | 28.68 | 0.00 | 16.67 | 33.33 | –33.33 | 83.33 | |
| Cycle 7 – cycle 1 | 42 | 13.29 | 29.68 | 0.00 | 4.17 | 33.33 | –41.67 | 91.67 | |
| Cycle 9 – cycle 1 | 14 | 24.40 | 32.27 | 0.00 | 16.67 | 41.67 | –16.67 | 91.67 | |
| Cycle 11 – cycle 1 | 9 | 20.37 | 25.38 | 0.00 | 25.00 | 33.33 | –25.00 | 58.33 | |
| Cycle 13 – cycle 1 | 5 | 20.00 | 25.41 | 0.00 | 8.33 | 33.33 | 0.00 | 58.33 | |
| Cycle 15 – cycle 1 | 2 | –4.17 | 5.89 | –8.33 | –4.17 | 0.00 | –8.33 | 0.00 | |
| EOT – cycle 1 | 15 | –17.22 | 25.29 | –33.33 | –16.67 | 8.33 | –66.67 | 16.67 | |
| Symptom | Cycle 3 – cycle 1 | 53 | –13.98 | 25.72 | –30.77 | –7.69 | 2.56 | –79.49 | 38.46 |
| Cycle 5 – cycle 1 | 47 | –14.57 | 27.68 | –35.90 | –5.13 | 2.56 | –79.49 | 33.33 | |
| Cycle 7 – cycle 1 | 42 | –13.74 | 26.69 | –33.33 | –5.13 | 5.13 | –76.92 | 25.64 | |
| Cycle 9 – cycle 1 | 14 | –29.67 | 27.28 | –58.97 | –23.08 | –7.69 | –74.36 | 5.13 | |
| Cycle 11 – cycle 1 | 9 | –23.93 | 23.47 | –43.59 | –28.21 | –2.56 | –51.28 | 7.69 | |
| Cycle 13 – cycle 1 | 5 | –19.49 | 22.98 | –38.46 | –25.64 | –5.13 | –41.03 | 12.82 | |
| Cycle 15 – cycle 1 | 2 | –11.54 | 16.32 | –23.08 | –11.54 | 0.00 | –23.08 | 0.00 | |
| EOT – cycle 1 | 15 | 10.77 | 30.80 | –12.82 | 7.69 | 28.21 | –43.59 | 74.36 | |
Abbreviations: EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer 30-item Quality of Life questionnaire; EOT, end of treatment; Q1, 1st quartile; Q3, 3rd quartile; SD, standard deviation.